MedTrace Logo

Cell Therapy as Treatment for Cerebral Palsy

NCT02241395 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-10-25

No results posted yet for this study

Summary

The purpose of this study was to study the effect of autologous bone marrow mononuclear cells on common symptoms of cerebral palsy patients.

Conditions

  • Cerebral Palsy

Interventions

BIOLOGICAL

Intrathecal autologous bone marrow mononuclear cell transplantation

Sponsors & Collaborators

  • Neurogen Brain and Spine Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Months
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-08-31
Primary Completion
2018-06-30
Completion
2018-12-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02241395 on ClinicalTrials.gov